Para Advisors’s NovoCure NVCR Stock Holding History

Para Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-20,000	Closed	-$290K	–	12
2016 Q1	$290K	Buy	+20,000	New	+$287K	1.09%	11

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Para Advisors's NVCR Position: Q2 2016 in Review

Para Advisors sold out of NovoCure (NVCR) in Q2 2016, closing a stake of 20,000 shares — an estimated $290K sold.

Para Advisors first reported a position in NVCR in Q1 2016 and held it in 1 quarter. The position peaked at $290K in Q1 2016. 66 funds tracked by Wall St. Rank hold NVCR as of Q2 2016.

Para Advisors reported no remaining NovoCure position as of Q2 2016 after selling out during the quarter.
Para Advisors sold 20,000 NovoCure shares in Q2 2016, an estimated $290K.
Para Advisors first reported a position in NovoCure in Q1 2016 and held it in 1 quarter.
Para Advisors's NovoCure position peaked at $290K in Q1 2016.
66 funds tracked by Wall St. Rank held NovoCure as of Q2 2016.

Based on Para Advisors's 13F filing for Q2 2016, filed 12 Aug 2016.